Dr. Harikrishnan Radhakrishnan

Dr. Harikrishnan Radhakrishnan

Translational Researcher
Qualification : Ph.D. in Integrative Oncology
Email : harikrir1@srmist.edu.in

Dr. Harikrishnan Radhakrishnan is a translational researcher specializing in cancer biology, synthetic immunology, cell-based therapeutics, and targeted drug delivery. He completed his Ph.D. in Translational Oncology at the Berlin School of Integrative Oncology (BSIO) and Charité – Universitätsmedizin Berlin Germany, followed by a DRS HONORS Postdoctoral Fellowship at Freie Universität Berlin. He subsequently spent over five years at SRI International, USA, progressing from Postdoctoral Fellow to Research Scientist and Program Director/Principal Investigator, where he led cell-based medicine programs and contributed to governmental and commercial projects, including NCI-supported research. He has contributed to research attracting over $1.3 million (USD) in funding and has authored numerous publications and patent applications. His current research focuses on developing programmable cell-based therapeutic and targeted delivery platforms for cancer, autoimmune and other complex diseases.

  • D. in Integrative Oncology (2018) – Charité - Universitätsmedizin Berlin, Germany
  • B.Tech. in Biotechnology (2012) – VIT University, Vellore, Tamil Nadu, India
  • 2026 - Present: Assistant Professor, Division of Medical Research, SRM Medical College Hospital and Research Center, Kattankulathur, Chennai, Tamil Nadu 603203, India
  • 2024 - 2025: Program Director/Principal Investigator (PD/PI), Research Scientist, Cell-based Medicine Lab, SRI Biosciences, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, United States.           
  • 2019 -2024: Postdoctoral Fellow, Cell-based Medicine Lab, SRI Biosciences, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, United States.
  • 2018 - 2018: DRS-Honors Postdoctoral Fellow, Translational Oncology of Solid Tumors Lab,Dahlem Research School-Freie Universitäts Berlin and Max-Delbrück-Center for Molecular Medizin, Berlin, Germany.
  • 2013 - 2018: Ph.D. Fellow, Translational Oncology of Solid Tumors Lab, ECRC - Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medizin, Berlin, Germany.
  • 2011 - 2013: Junior Researcher, Department of Stem cells, Lifeline Multispeciality Hospital, Tamil Nadu, India.
  • Immunology
  • Molecular cancer biology
  • Cancer therapeutics
  • Immunotherapy
  • Autoimmunity
  • Synthetic biology
  • Bioprocess engineering
  • Cell and gene therapy
  • regenerative medicine
  • Stem cell biology
  • Drug delivery
  • Drug repurposing

Funded Projects

  • Title : Pilot in vivo trial with T-cell-based delivery of immunostimulatory proteins
    Role: Principal Investigator (PI)
    Funding Agency: National Institute of Health (NIH)/ National Cancer Institute (NCI)
    Year & Duration: 2024 - 2026
    Sanctioned amount: $604,877 USD (approx. ₹50,327,339 )

Publications

Journal articles

  • Liu, M. A. Ssemadaali, H. Radhakrishnan etal., 2026. CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2. Molecular Medicine. 32 (45). doi: 10.1186/s10020-025-01420-1.
  • Newmyer, H. Radhakrishnan, H. S. Javitz etal., 2025. Syngenic CAR T cells engineered for persistent delivery of desired proteins. Journal of controlled release. doi: 10.1016/j.jconrel.2025.113960. Epub 2025 Jun 14
  • Radhakrishnan, S. Newmyer, H. S. Javitz etal., 2024. Engineered CD4 T cells for in vivo delivery of therapeutic proteins. Proceedings of the National Academy of Sciences. 121 (40) e2318687121. doi: 10.1073/pnas.2318687121.
  • Naidu, S. Karnati, H. Radhakrishnan, A. Gupta, 2024. Editorial article: Role of Non-coding RNAs (Emphasis on the Emerging Role of Circular RNAs) In Cancer. Application Potential for Molecular Diagnostics and Therapeutics of Cancer. Frontiers in Genetics - Sec. RNA. doi: 10.3389/fgene.2024.1450309.
  • Radhakrishnan, S. Newmyer, M. A. Ssemadaali etal., 2023. Primary T-cell-based delivery platform for in vivo synthesis of engineered proteins. Bioengineering and Translational Medicine. e10605. doi:10.1002/btm2.10605.
  • A. Ssemadaali, J. Arredondo, E. A. Buser, S. Newmyer, H. Radhakrishnan etal., 2023. Genetically engineered pair of cells for serological testing and its application for SARS-CoV2. Bioengineering and Translational Medicine. https://doi.org/10.1002/btm2.10508.
  • Newmyer, M. A. Ssemadaali, H. Radhakrishnan etal., 2022. Electrically Regulated Cell-based Intervention for Viral Infections. Bioengineering and Translational Medicine. e10434. doi: https://doi.org/10.1002/btm2.10434.
  • Kortum, H. Radhakrishnan, F. Zincke etal., 2022. Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis. Oncogene 41, 4446-4458.
  • A. Ssemadaali, S. Newmyer, H. Radhakrishnan etal., 2022. Cell-based platform for antigen testing and its application for SARS-CoV-2 infection. Microbiology Spectrum.
  • E. Repellin, M. A. Ssemadaali, S. Newmyer, H. Radhakrishnan etal., 2021. NK-Cell biofactory as an off-the-shelf cell-based vector for targetted in situ synthesis of engineered proteins. Advanced Biology, 2000298.
  • Radhakrishnan, H. S. Javitz, P. Bhatnagar, 2020. Lentivirus manufacturing process for primary T-cell biofactory production. Advanced Biosystems, 1900288.
  • Radhakrishnan, W. Walther, F Zincke etal., 2018. MACC1-the first decade of a key metastasis molecule from gene discovery to clinical translation. Cancer and Metastasis Reviews, 37(4): 805-820.
  • Radhakrishnan, K. Ilm, W. Walther etal., 2017. MACC1 regulates Fas mediated apoptosis through STAT1/3 – Mcl-1 signaling in solid cancers. Cancer Letters, 403: 231-245.
  • Somasundaram, R. Mishra, H. Radhakrishnan etal., 2015. Human adult stem cells maintain a constant phenotype profile irrespective of their origin, basal media, and long term cultures. Stem cell International, 146051.
  • Somasundaram, H. Radhakrishnan, R. Sankaran etal., 2015. Immunophenotypic comparison of heterogenous non-sorted versus sorted mononuclear cells from human umbilical cord blood: a novel cell enrichment approach. Cytotechnology, 67(1): 107-114.
  • Somasundaram, R. Mishra, H. Radhakrishnan etal., 2014. Lineage depletion of stromal vascular fractions isolated from human adipose tissue: a novel approach towards cell enrichment technology. Cytotechnology, 66: 219.
  • Marappagounder, I. Somasundaram, H. Radhakrishnan etal., 2013. Human omentum fat-derived mesenchymal stem cells transdifferentiates into pancreatic islet-like cluster. Cell Biochemistry and Function, 31(7): 612-619.
  • Somasundaram, H. Radhakrishnan, R. Mishra etal., 2013. Comparison of feto-maternal organ derived stem cells in facets of immunophenotype, proliferation and differentiation. Tissue and Cell, 45(6): 434-442.
  • Somasundaram, H. Radhakrishnan, R. Sankaran etal., 2013. Prospective biomarkers of stem cells of human endometrium and fallopian tube compared with bone marrow. Cell and Tissue Research, 352(3): 537-549.
  • Marappagounder, I. Somasundaram, LR. Philip etal., 2013. A comprehensive study on optimization of proliferation and differentiation potency of bone marrow derived mesenchymal stem cells under prolonged culture condition. Cytotechnology, 65(2): 187-197.

Patents

  • Bhatnagar, H. Radhakrishnan, 2023. Primary T-cell Biofactory chassis and delivery of immunostimulatory proteins. PCT/US2023/073035
  • Bhatnagar, H. Radhakrishnan, 2022. Genetically engineered tumor-specific effector cells for synthesis of enzymes. PCT/US2022/075123
  • Stein, D. Kobelt, B. Kortum, H. Radhakrishnan, W. Walther, 2020. Pharmaceutical combination of WNT signaling and MACC1 inhibitors. WO 2020/169812, PCT/EP2020/054641.

Book chapters

  • Somasundaram, R. Mishra, H. Radhakrishnan etal., 2015. Subcutaneous Adipose Tissue-Derived Stem Cells: Advancement and Applications in Regenerative Medicine. Regenerative Medicine (eds. Niranjan Bhattacharya, Phillip George Stubblefield). pp 91-112.
  • Somasundaram, H. Radhakrishnan, D. Marappagounder. 2015. Redundant Human Omentum Fat: A Leap Towards Regenerative Medicine. Regenerative Medicine (eds. Niranjan Bhattacharya, Phillip George Stubblefield). pp 125-133.
  • I. Somasundaram, H. Radhakrishnan, R. Mishra etal., 2014. Surface Antigenic Profiles of Stem Cells from the Human Bone Marrow, Subcutaneous Fat, and Omentum Fat. Stem cells in Aesthetic Procedures (eds. Melvin A. Shiffman, Alberto Di Giuseppe, Franco Bassetto). pp 41-66
  • 2018: Dahlem Research School (DRS) HONORS postdoctoral fellowship, Freie Universität Berlin
  • 2017: European Cell Death Organization (ECDO) Conference Scholarship
  • 2016: Promotionsstipendium, Charité - Universitätsmedizin Berlin, Germany
  • 2013: Berlin School of Integrative Oncology, Ph.D. Fellowship
  • 2011: University Merit Scholarship for the academic year 2010-2011
  • 2010: University Merit Scholarship for the academic year 2009-2010
  • 2010: Third prize, Paper presentation, Chemical engineering, Tathva-’10, NIT-Calicut, India

PhD Scholars

  • Name: Yuvadharini Tagore
    Email: yt4088@srmist.edu.in
    Education: MSc. Clinical Immunology
    Area of interest: Immuno-oncology 
  • Availability: Currently not available